ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Mergers & Acquisitions

Vical survives through reverse merger with Brickell

by Lisa Jarvis
June 7, 2019 | APPEARED IN VOLUME 97, ISSUE 23

 

Vical will stay alive through a reverse merger with privately held Brickell Biotech, which develops dermatology treatments. The combined company will have roughly $35 million in cash to support late-stage clinical studies of sofpironium bromide, Brickell’s anticholinergic for a form of excess sweating called axillary hyperhidrosis. In February, Vical laid off staff and said it was considering its options after ending development of its lead drug candidate, VL-2397.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment